THU0166 TREATMENT WITH UPADACITINIB IS ASSOCIATED WITH IMPROVEMENTS IN REVERSE CHOLESTEROL TRANSPORT IN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATION WITH CHANGES IN INFLAMMATION AND HDL LEVELS. (June 2019)

• Record Type: Journal Article
• Authors: Charles-Schoeman, Christina; Sornasse, Thierry; Sokolove, Jeremy
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 356
• Page End: 357
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.2983
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic morbidity and mortality. One mechanism by which inflammation may increase atherosclerotic progression is via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins with resultant reduction in HDL function. 1 Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe RA. Objectives: To assess the effect of UPA treatment on cholesterol efflux capacity (CEC) and evaluate the association of CEC with changes in inflammation and serum lipids. Methods: A subset of patients from the Phase 2 BALANCE II study 2 and the Phase 3 SELECT-NEXT study 3 were selected from the pool of patients with serum samples available at baseline and Week 12. Patients were matched for age and sex, and selected based on level of response to UPA therapy (BALANCE II, UPA 6 mg BID: 39 responders [mean change in DAS28-CRP at Week 12 -3.22] and 30 non-responders [mean change in DAS28-CRP -0.33]; SELECT-NEXT, UPA 15 mg QD: 20 responders [mean change in DAS28-CRP -3.78] and 20 non-responders [mean change in DAS28-CRP -0.67]). A demographically similar placebo (PBO) group without selection based on degree of response was also included (20 patients from each study). J774 macrophages labeled with [ 3 H]-cholesterol (treated with cAMP to express ABCA1 or left untreated) were exposed to patient sera. The difference between cholesterol efflux from serum-exposed and unexposed cells provided a measurement of CEC. Results were compared between the responder, non-responder, and PBO groups using Tukey's mean comparison method; correlations were calculated using the Pearson method; and all statistical analyses were performed in JMP 13.10 (SAS Institute). Results: In both studies, changes in global and ABCA1-dependent CEC, and to a lesser extent non-ABCA1-dependent CEC, were significantly higher in the UPA-treated group compared with the PBO group (Figure). In the BALANCE II study, there was a significant increase in CEC among UPA responders relative to PBO and a numerically apparent difference observed between UPA non-responders and PBO. Notably, in the SELECT-NEXT study, a similar and highly significant improvement in CEC was observed for both UPA-treated groups relative to PBO (without a significant difference between the responder and non-responder groups). Despite the lack of a consistent association between change in CEC and change in clinical disease activity, observed increases in CEC correlated significantly with reductions in CRP levels in all groups across all active treatment groups. Additionally, increases in CEC at Week 12 correlated well with changes in total blood cholesterol and HDL levels, but weakly with changes in blood low-density lipoprotein (LDL) levels. Conclusion: UPA treatment is associated with significant improvement in CEC. This effect was observed even among those demonstrating minimal clinical response (but not in those treated with PBO). The effect seems to be primarily driven by ABCA1-dependent cholesterol efflux and is strongly correlated with a rise in HDL cholesterol as well as reduction in systemic inflammation as measured by change in CRP. References: [1] Charles-Schoeman C, et al. Arthritis Rheumatol2017;69:46–57; [2] Genovese MC, et al. Arthritis Rheumatol2016;68:2857–66; [3] Burmester GR, et al. Lancet2018;391:2503–12 Acknowledgement: AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version. Medical writing support was provided by John Ewbank, PhD, of 2 the Nth. Disclosure of Interests: Christina Charles-Schoeman Grant/research support from: Bristol-Myers Squibb, AbbVie, and Pfizer, Consultant for: Regeneron-Sanofi, Pfizer, and Gilead, Thierry Sornasse Shareholder of: AbbVie, Employee of: AbbVie, Jeremy Sokolove Shareholder of: AbbVie, Employee of: AbbVie